Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.59 |
| ▸ | HPGD | P15428 | 5/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.50 |
| ▸ | TSHR | P16473 | 5/20 | 0.50 |
| ▸ | USP2 | O75604 | 6/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30663939 | 0.84 | ALDH1A1 (0.65) | ALDH1A1HSD17B10CYP3A4HPGDCYP2D6 | |
| SCHEMBL20804673 | 0.81 | ALDH1A1 (0.44) | ALDH1A1HSD17B10CYP3A4HPGDCYP2D6 | |
| SCHEMBL1556717 | 0.76 | ALDH1A1 (0.47) | ALDH1A1HSD17B10CYP3A4HPGDCYP2D6 | |
| SCHEMBL1556831 | 0.75 | CHRNB2 (0.60) | ALDH1A1HSD17B10CYP3A4HPGDCYP2D6 | |
| SCHEMBL20455775 | 0.75 | ALDH1A1 (0.83) | ALDH1A1HSD17B10CYP3A4HPGDCYP2D6 | |
| SCHEMBL18618236 | 0.74 | ALDH1A1 (0.51) | ALDH1A1HSD17B10CYP3A4HPGDCYP2D6 | |
| SCHEMBL2834740 | 0.74 | CYP3A4 (0.68) | ALDH1A1HSD17B10CYP3A4HPGDCYP2D6 | |
| SCHEMBL1555894 | 0.73 | ALDH1A1 (0.48) | ALDH1A1HSD17B10CYP3A4HPGDCYP2D6 | |
| SCHEMBL1555951 | 0.73 | ALDH1A1 (0.56) | ALDH1A1HSD17B10CYP3A4HPGDCYP2D6 | |
| SCHEMBL1426810 | 0.73 | CYP2D6 (0.82) | ALDH1A1HSD17B10CYP3A4HPGDCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4749715-B2 | — | — | 2011-08-17 | — | — | JP | claimed |
| EP-1519939-B9 | N-ARYL DIAZASPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT INC (US) | 2011-04-06 | — | — | EP | claimed |
| EP-1519939-B1 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT INC (US) | 2009-12-09 | — | — | EP | claimed |
| EP-1784184-A2 | THE USE OF N-ARYL DIAZASPIRACYCLIC COMPOUNDS IN THE TREATMENT OF ADDICTION | Targacept, Inc. (US) | 2007-05-16 | — | — | EP | claimed |
| US-20060058328-A1 | Use of N-aryl diazaspiracyclic compounds in the treatment of addiction | BHATTI BALWINDER S | 2006-03-16 | — | — | US | claimed |
| WO-2006023630-A2 | THE USE OF N-ARYL DIAZASPIRACYCLIC COMPOUNDS IN THE TREATMENT OF ADDICTION | TARGACEPT, INC. (US) | 2006-03-02 | — | — | WO | claimed |
| EP-1519939-A2 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | Targacept, Inc. (US) | 2005-04-06 | — | — | EP | claimed |
| US-20040067930-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TARGACEPT, INC. | 2004-04-08 | — | — | US | claimed |
| WO-2004005293-A2 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT, INC. (US) | 2004-01-15 | — | — | WO | claimed |
| US-20200048267-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-13 | — | — | US | disclosed |
| WO-2018141984-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-09 | — | — | WO | disclosed |
| US-20110105548-A1 | N-ARYL DIAZASPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-7923559-B2 | 7-(3-pyridyl)-1,7-diazaspiro[4.4]nonane; mania, anxiety, dyslexia, schizophrenia, depression, obsessive-compulsive disorders, Tourette's syndrome | TARGACEPT, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| EP-1519939-B9 | N-ARYL DIAZASPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT INC (US) | 2011-04-06 | — | — | EP | disclosed |
| US-20060217406-A1 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | BHATTI BALWINDER S | 2006-09-28 | — | — | US | disclosed |
| US-20060058328-A1 | Use of N-aryl diazaspiracyclic compounds in the treatment of addiction | BHATTI BALWINDER S | 2006-03-16 | — | — | US | disclosed |
| WO-2006023630-A2 | THE USE OF N-ARYL DIAZASPIRACYCLIC COMPOUNDS IN THE TREATMENT OF ADDICTION | TARGACEPT, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20050272739-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | BHATTI BALWINDER S | 2005-12-08 | — | — | US | disclosed |
| US-6956042-B2 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2005-10-18 | — | — | US | disclosed |
| US-20040067930-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TARGACEPT, INC. | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105548-A1 | N-ARYL DIAZASPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TNNC1, ACHE, CHRNA6 | ALDH1A1 1667/4885HSD17B10 2696/4885CYP3A4 125/4885 |
| US-20200048267-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | ALDH1A1 3839/4885HSD17B10 2463/4885CYP3A4 4278/4885 |
| US-20060217406-A1 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TNNC1, ACHE, CHRNA6 | ALDH1A1 1337/4885HSD17B10 2582/4885CYP3A4 140/4885 |
| US-20050272739-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TNNC1, ACHE, CHRNA6 | ALDH1A1 1337/4885HSD17B10 2582/4885CYP3A4 140/4885 |
| US-20060058328-A1 | Use of N-aryl diazaspiracyclic compounds in the treatment of addiction | OPRD1, OPRK1, OPRL1 | ALDH1A1 1126/4885HSD17B10 1206/4885CYP3A4 105/4885 |
| US-20040067930-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TNNC1, ACHE, CHRNA6 | ALDH1A1 1337/4885HSD17B10 2582/4885CYP3A4 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.